Cite
HARVARD Citation
Balamurgan, R. et al. (2022). IDF21-0338 Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients. Diabetes research and clinical practice. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Balamurgan, R. et al. (2022). IDF21-0338 Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients. Diabetes research and clinical practice. p. . [Online].